They revealed that the concentrations of serum biomarkers such as NSE, CYFRA 21-1, CEA, and CA125 are significantly higher in lung cancer than in pulmonary benign diseases, and various biomarker panels were found to increase the sensitivity and improve the accuracy of the diagnosis of lung cancer. The gene discussed is MUC16; the disease is lung carcinoma.